Formulation and Evaluation of Trimetazidine Dihydrochloride Extended Release Tablets by Melt Congealing Method

Trimetazidine dihydrochloride, a cellular antiischemic agent indicated in the management and prophylaxis of angina pectoris is given as 20 mg thrice daily in the conventional dosage regimen. The purpose of the present study was to formulate and evaluate twice a day extended release tablets containin...

Descripción completa

Detalles Bibliográficos
Autores principales: Javeer, S. D., Pandit, Reshma, Jain, S. P., Amin, Purnima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2010
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178970/
https://www.ncbi.nlm.nih.gov/pubmed/21969741
http://dx.doi.org/10.4103/0250-474X.84578
Descripción
Sumario:Trimetazidine dihydrochloride, a cellular antiischemic agent indicated in the management and prophylaxis of angina pectoris is given as 20 mg thrice daily in the conventional dosage regimen. The purpose of the present study was to formulate and evaluate twice a day extended release tablets containing 30 mg trimetazidine dihydrochloride. The method developed to formulate these extended release tablets was melt congealing followed by wet granulation which exhibited uniform sustained release action and overcame the drawbacks of multidosing. The formulation was developed with Methocel(®) K100M and stearic acid as release retardant.

Ejemplares similares